Skip to main content
Top
Published in: Child's Nervous System 5/2019

01-05-2019 | Medulloblastoma | Case Report

Old drugs still work! Oral etoposide in a relapsed medulloblastoma

Authors: Marta Perez-Somarriba, Maitane Andión, Miguel A. López-Pino, Cinzia Lavarino, Luis Madero, Alvaro Lassaletta

Published in: Child's Nervous System | Issue 5/2019

Login to get access

Abstract

Medulloblastoma is the most common malignant brain tumor in children. Approximately 30% of children with medulloblastoma will progress or relapse despite being treated. New therapies have been proposed in recent years, including high-dose chemotherapy, immunotherapy, and targeted therapy. However, the best treatment for these patients remains unclear, and in this situation prognosis is poor. Oral etoposide has been used as a single agent or in combination for treating relapsed brain tumors since the 1990s. We report an 8-year-old patient with recurrent metastatic medulloblastoma who had an excellent response after treatment with oral etoposide, maintaining a great quality of life. As clinicians, we must always try to include our patients in clinical trials; however, when this is not possible, we should not forget that “old drugs” such as oral etoposide may work in some patients, with a good response of the tumor, and what is most important, providing the patient with a good quality of life.
Literature
1.
go back to reference Scheinemann K, Bouffet E (2015) Pediatric neuro-oncology. Springer. Chapter 12. Embryonal brain tumors (127–138) Scheinemann K, Bouffet E (2015) Pediatric neuro-oncology. Springer. Chapter 12. Embryonal brain tumors (127–138)
2.
go back to reference Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC (2017) Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 18(7):958–971CrossRefPubMedPubMedCentral Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC (2017) Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 18(7):958–971CrossRefPubMedPubMedCentral
3.
go back to reference Nygaard R, Kivivuori SM (2012) Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy. Anti-Cancer Drugs 23(3):342–346CrossRefPubMed Nygaard R, Kivivuori SM (2012) Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy. Anti-Cancer Drugs 23(3):342–346CrossRefPubMed
4.
go back to reference Ruggiero A, Rizzo D, Attin G et al (2010) Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. Eur J Cancer 46(16):2943–2949CrossRefPubMed Ruggiero A, Rizzo D, Attin G et al (2010) Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. Eur J Cancer 46(16):2943–2949CrossRefPubMed
5.
go back to reference Pizer B, Donachie P, Robinson K et al (2011) Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children’s Cancer and Leukaemia Group study. Eur J Cancer 47:1389–1397CrossRefPubMed Pizer B, Donachie P, Robinson K et al (2011) Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children’s Cancer and Leukaemia Group study. Eur J Cancer 47:1389–1397CrossRefPubMed
6.
go back to reference Needle MN, Molloy PT, Geyer JR, Herman-Liu A, Belasco JB, Goldwein JW, Sutton L, Phillips PC (1997) Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29(1):28–32CrossRefPubMed Needle MN, Molloy PT, Geyer JR, Herman-Liu A, Belasco JB, Goldwein JW, Sutton L, Phillips PC (1997) Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29(1):28–32CrossRefPubMed
7.
go back to reference Chamberlain MC, Kormanik PA (1997) Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol 17(3):230–234CrossRefPubMed Chamberlain MC, Kormanik PA (1997) Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol 17(3):230–234CrossRefPubMed
8.
go back to reference Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D (1996) Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14(6):1922–1927CrossRefPubMed Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D (1996) Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14(6):1922–1927CrossRefPubMed
9.
go back to reference Peryl A, Chocholous M, Kieran M et al (2012) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 59(3):511–517CrossRef Peryl A, Chocholous M, Kieran M et al (2012) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 59(3):511–517CrossRef
10.
go back to reference Robison N, Campigotto F, Chi SN et al (2014) A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 61(3):636–642CrossRefPubMed Robison N, Campigotto F, Chi SN et al (2014) A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 61(3):636–642CrossRefPubMed
11.
go back to reference Bautista F, Fioravantti V, de Rojas T, Carceller F, Madero L, Lassaletta A, Moreno L (2017) Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. Cancer Med 6(11):2606–2624CrossRefPubMedPubMedCentral Bautista F, Fioravantti V, de Rojas T, Carceller F, Madero L, Lassaletta A, Moreno L (2017) Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. Cancer Med 6(11):2606–2624CrossRefPubMedPubMedCentral
12.
go back to reference Dhall G, Grodman H, Sands S et al (2008) Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start I and II” protocols. Pediatr Blood Cancer 50:1169–1175CrossRefPubMed Dhall G, Grodman H, Sands S et al (2008) Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start I and II” protocols. Pediatr Blood Cancer 50:1169–1175CrossRefPubMed
13.
go back to reference Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27(11):573–581CrossRefPubMed Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27(11):573–581CrossRefPubMed
14.
go back to reference Gomez S, Garrido-Garcia A, Garcia-Gerique L et al (2018) A novel method for rapid molecular subgrouping of medulloblastoma. Clin Cancer Res 24(6):1355–1363CrossRefPubMed Gomez S, Garrido-Garcia A, Garcia-Gerique L et al (2018) A novel method for rapid molecular subgrouping of medulloblastoma. Clin Cancer Res 24(6):1355–1363CrossRefPubMed
15.
go back to reference Davidson A, Gowing R, Lowis S, Newell D, Lewis I, Dicks-Mireaux C, Pinkerton CR (1997) Phase II study of 21 day schedule oral etoposide in children. Eur J Cancer 33(11):1816–1822CrossRefPubMed Davidson A, Gowing R, Lowis S, Newell D, Lewis I, Dicks-Mireaux C, Pinkerton CR (1997) Phase II study of 21 day schedule oral etoposide in children. Eur J Cancer 33(11):1816–1822CrossRefPubMed
16.
go back to reference Korones D, Smith A, Foreman N, Bouffet E (2006) Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer 47(3):37–41CrossRefPubMed Korones D, Smith A, Foreman N, Bouffet E (2006) Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer 47(3):37–41CrossRefPubMed
17.
go back to reference Esbenshade AJ, Kocak M, Hershon L et al (2017) A phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): a report from the Children’s Oncology Group. Pediatr Blood Cancer 64(6):1–8CrossRef Esbenshade AJ, Kocak M, Hershon L et al (2017) A phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): a report from the Children’s Oncology Group. Pediatr Blood Cancer 64(6):1–8CrossRef
18.
go back to reference Le Deley MC, Vassal G, Tabi A, Shamsaldin A, Leblanc T, Hartmann O (2005) High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 45:25–31CrossRefPubMed Le Deley MC, Vassal G, Tabi A, Shamsaldin A, Leblanc T, Hartmann O (2005) High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 45:25–31CrossRefPubMed
19.
go back to reference Ezoe S (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9(7):2444–2453CrossRefPubMedPubMedCentral Ezoe S (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9(7):2444–2453CrossRefPubMedPubMedCentral
20.
go back to reference Winick NJ, McKenna RW, Shuster JJ et al (1993) Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11(2):209–217CrossRefPubMed Winick NJ, McKenna RW, Shuster JJ et al (1993) Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11(2):209–217CrossRefPubMed
21.
go back to reference Le Deley MC, Leblanc T, Shamsaldin A et al (2003) Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societé Française d’Oncologie Pédiatrique. J Clin Oncol 21(6):1074–1081CrossRefPubMed Le Deley MC, Leblanc T, Shamsaldin A et al (2003) Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societé Française d’Oncologie Pédiatrique. J Clin Oncol 21(6):1074–1081CrossRefPubMed
22.
go back to reference Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472CrossRefPubMed Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472CrossRefPubMed
23.
go back to reference Ramaswamy V, Remke M, Eric Bouffet E et al (2013) Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 14(12):1200–1207CrossRefPubMedPubMedCentral Ramaswamy V, Remke M, Eric Bouffet E et al (2013) Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 14(12):1200–1207CrossRefPubMedPubMedCentral
Metadata
Title
Old drugs still work! Oral etoposide in a relapsed medulloblastoma
Authors
Marta Perez-Somarriba
Maitane Andión
Miguel A. López-Pino
Cinzia Lavarino
Luis Madero
Alvaro Lassaletta
Publication date
01-05-2019
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 5/2019
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-019-04072-9

Other articles of this Issue 5/2019

Child's Nervous System 5/2019 Go to the issue